Skip to content
StackItSmart
AHuman RCT or meta-analysis
High riskNeuropsychiatric

Testosterone Enanthate

Test E

Testosterone enanthate ("Test E") is a long-acting, oil-based injectable ester of testosterone, the primary male androgen. In medicine it is used as testosterone-replacement therapy (TRT) for men with diagnosed hypogonadism; outside medicine it is the backbone of most anabolic-androgenic steroid (AAS) regimens, taken at supraphysiologic doses to increase muscle size and strength. It reliably works as an anabolic agent, but that same androgen exposure drives the dangers: it strongly suppresses the body's own testosterone production and sperm output (often causing infertility and testicular shrinkage), raises red-blood-cell mass (erythrocytosis/polycythemia) which increases clot and cardiovascular-event risk, lowers HDL ("good") cholesterol, and — with long-term supraphysiologic misuse — is associated with reduced heart-pumping/relaxation function and accelerated coronary plaque. Estrogen-related effects (gynecomastia, water retention) and neuropsychiatric effects (irritability, hypomania in a minority at high doses) also occur. This is educational information only, not medical advice; these substances carry serious risks and require a qualified physician and regular bloodwork. 21+ only.

Clinical readoutAAS · injectable-testosterone
Hepatic strainLow
CardiovascularModerate
HPTA suppressionVery high
Half-life
4.5 d
Route
Deep intramuscular inje…
Evidence
A
Active
Clinically active for r…
4.5 d9 d13.5 d18 d3.2 wk
Illustrative single-compartment washout · each mark = one half-life · t½ ≈ The enanthate ester prolongs release; the terminal elimination half-life of injected testosterone enanthate is on the order of ~4.5 days (primate/preclinical PK data; no rigorous single-dose human half-life RCT identified).
Pharmacology

Mechanism of action

Testosterone enanthate is a prodrug: the heptanoic-acid (enanthate) ester is cleaved by serum esterases after intramuscular injection to release free testosterone, which extends the release from the oil depot. Testosterone binds the intracellular androgen receptor to drive gene transcription that increases muscle protein synthesis and erythropoiesis (red-cell production). It is amplified in some tissues by 5-alpha-reductase to dihydrotestosterone (DHT; androgenic effects on skin, hair, prostate) and aromatized by aromatase to estradiol (estrogenic effects such as gynecomastia and effects on bone, fat, and lipids). Exogenous testosterone suppresses hypothalamic GnRH and pituitary LH/FSH via negative feedback, shutting down endogenous testicular testosterone and sperm production.
Kinetics

Pharmacokinetics

Half-life

The enanthate ester prolongs release; the terminal elimination half-life of injected testosterone enanthate is on the order of ~4.5 days (primate/preclinical PK data; no rigorous single-dose human half-life RCT identified).

Active duration

Clinically active for roughly 2-3 weeks per intramuscular injection; supraphysiologic serum concentrations peak within the first days and decline over 1-2 weeks, which is why replacement dosing intervals are typically every 1-3 weeks.

Route

Deep intramuscular injection of an oil-based depot.

Metabolism & clearance

Hepatic metabolism of released testosterone (reduction and oxidation to inactive metabolites; conjugation) with renal excretion of conjugated metabolites; peripheral conversion to DHT (5-alpha-reductase) and estradiol (aromatase). Clearance is slower in older men. PK is described here only for washout/monitoring and clinician discussion, never for evading testing.

For monitoring and washout planning, not drug-test evasion.

Reported effects

Physiological & performance effects

  • Increases fat-free mass, muscle cross-sectional area, and maximal strength; effects are dose-related and larger when combined with resistance training (demonstrated in RCTs at supraphysiologic doses)
  • Raises hemoglobin and hematocrit (erythropoietic effect), dose-dependently
  • Restores/raises serum testosterone and its metabolites (DHT, estradiol) and relieves symptoms of testosterone deficiency in hypogonadal men
  • Suppresses pituitary LH/FSH and endogenous testosterone and sperm production
  • Lowers HDL-cholesterol
  • Reported replacement dosing in the literature is roughly 75-100 mg weekly or ~150-250 mg every 2-3 weeks (e.g., mean ~229 mg every 26 days); research/misuse supraphysiologic doses of 300-600 mg weekly were used in controlled trials and carry substantially higher rates of adverse effects — these figures are descriptive, not a recommendation
Safety

Adverse effects by system

Cardiovascular

In middle-aged/older hypogonadal men with high CV risk, guideline-dose transdermal TRT was noninferior to placebo for major adverse cardiac events but showed higher rates of atrial fibrillation and pulmonary embolism (TRAVERSE RCT). Long-term supraphysiologic AAS misuse is associated with reduced left-ventricular systolic and diastolic function and accelerated, dose-related coronary atherosclerosis (observational). HDL-cholesterol is lowered. Developing polycythemia on therapy raises MACE/VTE risk.

Hepatic

Injectable testosterone esters are far less hepatotoxic than 17-alpha-alkylated oral steroids, but testosterone and its derivatives have been linked to cholestasis, peliosis hepatis, and hepatic tumors, chiefly with supraphysiologic/long-term exposure; most injury is reversible on discontinuation though some consequences are not (review-level evidence).

Endocrine / HPTA

Potent, dose-dependent suppression of the hypothalamic-pituitary-gonadal axis: LH/FSH and endogenous testosterone production are shut down. Aromatization raises estradiol, which can cause gynecomastia and fluid retention.

Reproductive

Suppression of spermatogenesis causing oligo-/azoospermia and infertility, and testicular atrophy. Fertility often recovers after cessation but recovery is variable and can be prolonged or, in some, incomplete.

Neuropsychiatric

At physiologic-to-moderate doses, effects on mood are generally minimal in controlled studies; however, at higher supraphysiologic doses (around 500 mg/week and above) a minority of men develop irritability, aggression, or hypomanic/manic symptoms. Dependence and withdrawal (including depressed mood) are described with AAS misuse.

Renal

A higher incidence of acute kidney injury was observed in the testosterone group vs placebo in the TRAVERSE RCT. Direct nephrotoxicity from testosterone itself is not well established; secondary strain (e.g., from polycythemia/dehydration) is a concern. Limited high-quality renal data.

Hematologic

Dose-dependent rise in hemoglobin/hematocrit (erythrocytosis/secondary polycythemia); when hematocrit reaches polycythemic thresholds (>=52%) the risk of major adverse cardiovascular and venous thromboembolic events is increased.

Dermatologic

Androgenic skin effects — acne, oily skin, and accelerated male-pattern scalp hair loss in genetically predisposed individuals — are recognized expected consequences of increased androgen exposure; controlled quantification at supraphysiologic doses is limited.

Recovery

HPTA suppression & recovery

Suppression: Severe and expected — exogenous testosterone reliably and dose-dependently suppresses LH/FSH and endogenous testosterone and sperm production.

After stopping, spontaneous recovery of the HPG axis and spermatogenesis occurs in many men if given sufficient time, but the timeline is variable and recovery can be incomplete, especially after prolonged or high-dose use. Any recovery approach should be directed by an endocrinologist and individualized; where pharmacologic assistance is considered, only single-agent (single-SERM) approaches are within scope here and dual-SERM protocols are not described. Men wishing to preserve fertility should consult a clinician before starting.

Bloodwork & vitals

Monitoring

Recommended labs & checks
Serum total testosterone (to assess exposure)Hematocrit/hemoglobin (CBC) — key safety lab for erythrocytosisPSA and prostate evaluation (per age/risk)Lipid panel (HDL and overall lipids)Liver function tests (AST/ALT, bilirubin)Estradiol where gynecomastia/fluid retention is a concernBlood pressure

Cadence: Baseline before starting; re-evaluate symptoms, adverse effects, hematocrit, testosterone, and prostate-cancer risk during the first 3-12 months, then at least annually per Endocrine Society guidance. Hold/reduce and seek clinician input if hematocrit reaches polycythemic thresholds (commonly ~52-54%).

Warning signs — seek care
  • Chest pain, shortness of breath, leg swelling/pain (possible clot/pulmonary embolism) — seek emergency care
  • Palpitations or irregular heartbeat (atrial fibrillation)
  • Ruddy/flushed complexion, headaches, visual changes (possible high hematocrit)
  • Reduced urine output or swelling (possible acute kidney injury)
  • New breast tenderness/enlargement (gynecomastia)
  • Marked mood change, aggression, or manic/depressive symptoms
  • Jaundice, dark urine, right-upper-quadrant pain (possible liver injury)
  • Testicular shrinkage or infertility concerns
Do not use if

Contraindications

  • Breast or prostate cancer
  • Palpable prostate nodule/induration, or PSA >4 ng/mL (or >3 ng/mL in men at increased prostate-cancer risk) without urological evaluation
  • Elevated hematocrit (erythrocytosis/polycythemia)
  • Men planning fertility in the near term
  • Untreated severe obstructive sleep apnea
  • Severe lower urinary tract symptoms
  • Uncontrolled heart failure
  • Myocardial infarction or stroke within the prior 6 months
  • Thrombophilia / high thrombotic risk
  • Pre-existing significant liver disease (relative caution)
Combinations

Interaction profile

  • MajorWith another anabolic steroid: Additive cardiovascular strain
  • MajorWith a thermogenic stimulant: Additive cardiovascular strain
  • ModerateWith thyroid hormone: Additive cardiovascular strain
  • ModerateWith growth hormone: Additive cardiovascular strain
  • MajorWith another anabolic steroid: Blood / clotting
  • MajorWith a clot-promoting SERM: Blood / clotting
  • ModerateWith an aromatase inhibitor: Hormonal
  • ModerateWith an anabolic steroid: Hormonal
  • ContraindicatedWith DNP: Additive cardiovascular strain

Check a specific combination in the interaction checker.

Harm reduction

Reducing harm & when to stop

  • This is educational information only, not medical advice, and does not create a doctor-patient relationship; management belongs with a qualified physician.
  • Do not use without a genuine medical indication and clinician oversight; obtain baseline bloodwork before any use and monitor on an ongoing basis.
  • Hematocrit is the single most important routine safety lab — a rising or high hematocrit (approaching ~52-54%) signals increased clot/cardiovascular-event risk and should prompt stopping and urgent clinician review.
  • Seek emergency care for chest pain, breathlessness, one-sided leg swelling/pain (possible clot or pulmonary embolism), or stroke-like symptoms.
  • Stop and consult a clinician for jaundice or right-upper-quadrant pain (possible liver injury), uncontrolled high blood pressure, marked mood disturbance/aggression, or new breast enlargement.
  • Expect suppression of natural testosterone and fertility; if fertility matters, discuss preservation with a clinician before starting. Recovery of the HPG axis is variable and should be managed by an endocrinologist (single-agent approaches only are in scope here).
  • Higher/supraphysiologic doses escalate every risk (cardiac, lipid, hematologic, hepatic, psychiatric); the literature reports dose ranges but none of this is a recommendation to use or to maximize dose.
  • Report all substances to your clinician so lab findings and cardiovascular/thrombotic risk can be interpreted correctly.
Evidence

Citations (12)

Every clinical claim above is tied to a primary source. Overall evidence grade A — graded to the best available evidence for its core claims.

  1. 01

    Supraphysiologic testosterone enanthate (600 mg/week for 10 weeks) increases fat-free mass, muscle size, and strength, with larger gains when combined with resistance training; no mood/behavior change was seen in this RCT.

    RCTThe effects of supraphysiologic doses of testosterone on muscle size and strength in normal men.PMID 8637535 ↗

  2. 02

    Testosterone's anabolic effects and rises in hemoglobin/hematocrit are dose-related; supraphysiologic doses (up to 600 mg/week) produce significant muscle/strength gains but a high frequency of adverse effects (hematocrit >54%, leg edema, prostate events); older men have lower testosterone clearance.

    RCTOlder men are as responsive as young men to the anabolic effects of graded doses of testosterone on the skeletal muscle.PMID 15562020 ↗

  3. 03

    In middle-aged/older hypogonadal men with high CV risk, guideline-dose TRT was noninferior to placebo for major adverse cardiac events but showed higher rates of atrial fibrillation, pulmonary embolism, and acute kidney injury.

    RCTCardiovascular Safety of Testosterone-Replacement Therapy.PMID 37326322 ↗

  4. 04

    Long-term supraphysiologic AAS use is associated with reduced left-ventricular systolic and diastolic function and accelerated, dose-related coronary atherosclerosis.

    CohortCardiovascular Toxicity of Illicit Anabolic-Androgenic Steroid UsePMID 28533317 ↗

  5. 05

    Developing secondary polycythemia (hematocrit >=52%) while on testosterone therapy independently increases the risk of major adverse cardiovascular events and venous thromboembolism in the first year.

    CohortSecondary Polycythemia in Men Receiving Testosterone Therapy Increases Risk of Major Adverse Cardiovascular Events and Venous Thromboembolism in the First Year of Therapy.PMID 35050717 ↗

  6. 06

    Testosterone/AAS suppress the hypothalamic-pituitary-gonadal axis and spermatogenesis; after cessation, spontaneous recovery occurs in many men over time but is variable and may be incomplete.

    ReviewRecovery of spermatogenesis following testosterone replacement therapy or anabolic-androgenic steroid use.PMID 26908067 ↗

  7. 07

    At doses up to ~500 mg/week most men show minimal mood effects, but a minority can develop irritability/hypomanic or manic symptoms at high supraphysiologic doses.

    RCTPsychosexual effects of three doses of testosterone cycling in normal men.PMID 10023498 ↗

  8. 08

    Exogenous androgens/testosterone lower HDL-cholesterol.

    ReviewAndrogens and coronary artery disease.PMID 12700179 ↗

  9. 09

    Testosterone and its derivatives are associated with hepatic cholestasis, peliosis hepatis, and hepatic tumors (chiefly with supraphysiologic/long-term use), usually reversible on discontinuation; injectable esters are far less hepatotoxic than 17-alpha-alkylated oral steroids.

    ReviewAnabolic androgenic steroid-induced liver injury: An update.PMID 36051334 ↗

  10. 10

    Testosterone enanthate is used for replacement at intervals of roughly 2-3 weeks (e.g., mean ~229 mg every 26 days), and monitoring includes testosterone, estradiol, DHT, lipids, and prostate parameters.

    CohortLong-term efficacy and safety of a permeation-enhanced testosterone transdermal system in hypogonadal men.PMID 9497881 ↗

  11. 11

    Contraindications (breast/prostate cancer, PSA thresholds, elevated hematocrit, near-term fertility, severe OSA, severe LUTS, uncontrolled heart failure, recent MI/stroke, thrombophilia) and a monitoring plan (testosterone, hematocrit, prostate-cancer risk, especially in the first year) are recommended by the Endocrine Society guideline.

    GuidelineTestosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline.PMID 29562364 ↗

  12. 12

    The terminal elimination half-life of testosterone enanthate is on the order of ~4-5 days (primate PK data).

    PreclinicalPharmacokinetics and pharmacodynamics of testosterone enanthate and dihydrotestosterone enanthate in non-human primates.PMID 2333732 ↗

Last reviewed 2026-07-06 · Verified against PubMed · Educational, not medical advice